Dataset:23264438 Search Result
Clinical Information
Subject demographics and clinical outcome
Subjecta (n=7) Age (gender) Body weight, kg Underlying condition Lymphocyte count at enrolment, ×103 cells/μl Treatment Dose,every 8 h CrCl, ml/minb Virus subtype (resistant drug) Viral load at baseline, log10 RNA copies/mlc Viral load reduction, log10 RNA copies/ml Duration of viral shedding, days Clinical outcome Adverse events
1-1 17 (M) 58 CBT (day 24) 0.2 OSL monotherapy 50 mg OSL+ 75 mg AMT 109 2009 H1N1 (AMT) 5.7 1.6 with rebound at day 7 72 Required second course of treatment Acute GVHD (gut)
1-2 72 (M) 91 T-cell lymphoma 0.7 TCAD 200 mg RBV+ 50 mg OSL+ 75 mg AMT 121 H3N2 (AMT) BLODd – Response by day 10 None
1-3 47 (F) 67 Unrelated BMT (day 17) 0.05 TCAD 200 mg RBV+ 50 mg OSL+ 37.5 mg AMT 148 NDe BLOD – Response by day 10
2-1 58 (M) 107 Unrelated PBSCT (day 1,859) 2.7 TCAD 200 mg RBV+ 50 mg OSL+ 75 mg AMT 47 ND BLOD – Response by day 10
2-2 45 (F) 88 Autologous PBSCT (day 3) BLOD TCAD 200 mg RBV+ 50 mg OSL+ 50 mg AMT 157 2009 H1N1 (AMT) 5.2 Withdrew on day 5, no reduction Withdrew with viral detection Withdrew on day 5, no response Acute RDS
2-3 9 (F) 27 CBT (day 2,084) 0.4 TCAD 150 mg RBV+ 40 mg OSL+ 50 mg AMT 117 H3N2 (AMT) 6.9 >3.9 >9–<27f Response by day 10 None
2-4 6 (M) 26 ALL 1.2 TCAD 150 mg RBV+ 40 mg OSL 166 H1N1 (OSL) 4.6 >1.6 8 Response by day 10 None
aStudy 1 is a randomized study and study 2 is an open-label study of triple-combination antiviral drug (TCAD).
bPaediatric renal clearance calculated using Schwartz equation; Cockcroft-Gault calculation used for adults.
cDetermined by quantitative PCR.
d3 log10 RNA copies/ml for viral load.
eNot determined (ND) as a result of low viral load.
fNo tests were done between day 9 and day 27, and day 28 was negative. ALL, acute lymphocytic leukaemia; ALP, alkaline phosphatase; AMT, amantadine; BLOD, below limit of detection; BMT, bone marrow transplantation; CBT, cord blood transplantation; CrCl, creatine clearance; F, female; GGT, γ-glutamyl transferase; GVHD, graft-versus-host disease; M, male; OSL, oseltamivir; PBSCT, peripheral blood stem cell transplant; RBV, ribavirin; RDS, respiratory distress syndrome.